2022
Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy
Harold JA, Casilla-Lennon M, Kenney PA, Ratner ES. Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy. BMJ Case Reports 2022, 15: e245015. PMID: 35383096, PMCID: PMC8984011, DOI: 10.1136/bcr-2021-245015.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAgedCystectomyFemaleHumansUrinary BladderUrinary Bladder DiseasesUrinary Bladder NeoplasmsConceptsClear cell adenocarcinomaPartial cystectomyCell adenocarcinomaMüllerian originPAX-8 stainingExtensive endometriosisAdjuvant therapyFinal pathologyTotal hysterectomyTransurethral resectionBladder massResidual tumorCystectomyAdenocarcinomaHysterectomyEndometriosisResectionTherapyTumorsPathologyWomen
2021
Cachexia and bladder cancer: clinical impact and management
Lokeshwar SD, Press BH, Nie J, Klaassen Z, Kenney PA, Leapman MS. Cachexia and bladder cancer: clinical impact and management. Current Opinion In Supportive And Palliative Care 2021, 15: 260-265. PMID: 34698663, DOI: 10.1097/spc.0000000000000580.Peer-Reviewed Original ResearchMeSH KeywordsCachexiaCystectomyHumansPalliative CareSarcopeniaTumor MicroenvironmentUrinary Bladder NeoplasmsConceptsRadical cystectomyBladder cancerPharmacological agentsManagement of cachexiaNovel pharmaceutical agentsPostoperative complicationsWorse survivalMultidisciplinary managementClinical outcomesHypercatabolic statePalliative carePoor outcomeClinical trialsNutritional supplementationBCa patientsClinical impactPhysical therapyCachexiaRadiation therapyHuman studiesPatientsTherapeutic outcomesNutritional deficienciesNutritional supplementsTumor microenvironment
2019
Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?
Syed JS, Abello A, Nguyen J, Lee AJH, Desloges JJ, Leapman MS, Kenney PA. Outcomes for urologic oncology procedures: are there differences between academic and community hospitals? World Journal Of Urology 2019, 38: 1187-1193. PMID: 31420696, DOI: 10.1007/s00345-019-02902-8.Peer-Reviewed Original ResearchConceptsLength of stayCommunity hospitalAcademic hospitalReadmission ratesRadical cystectomyHospital-based outcomesDirect costsMean direct costUrologic oncology proceduresStudent's t-testCase mix indexIndex admissionVizient databaseRadical nephroureterectomyPartial cystectomySurgical treatmentUrologic malignanciesOncologic proceduresPartial nephrectomyCystectomyOncology proceduresAcademic centersHospitalProstatectomyStay
2010
Novel ZEB1 expression in bladder tumorigenesis
Kenney PA, Wszolek MF, Rieger‐Christ K, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 expression in bladder tumorigenesis. BJU International 2010, 107: 656-663. PMID: 20735391, DOI: 10.1111/j.1464-410x.2010.09489.x.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTransitional cell carcinomaZEB1 expressionNuclear ZEB1 expressionTissue microarrayBladder tumorsTumor progressionGrade I/IIBladder tumorigenesisMuscle-invasive UCBCancer-specific survivalGrade III tumorsNormal bladder mucosaExpression levelsExpression of ZEB1Underlying cellular changesCell linesBladder cell linesUM-UC-3Bladder tumor progressionProtein expression levelsBladder carcinoma cell lineInvasive UCBWestern blot analysisNodal involvementIdentification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays
Gould JJ, Kenney PA, Rieger-Christ KM, Neto B, Wszolek MF, LaVoie A, Holway AH, Spurrier B, Austin J, Cammarata BK, Canes D, Libertino JA, Summerhayes IC. Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays. Journal Of Urology 2010, 183: 2395-2402. PMID: 20403623, DOI: 10.1016/j.juro.2010.02.004.Peer-Reviewed Original ResearchConceptsReverse phase protein arrayPhase protein arrayHistone deacetylase inhibitorsInvasive cell linesDeacetylase inhibitorsProtein arraysExpression profilesCell linesProtein expression profilesMS-275Specific protein groupsSuppressor gene expressionHigh-throughput screeningGene expressionGene modulatorsTrichostatin AInvasive linesSuppressor geneBladder carcinoma cell lineProtein groupsFAK expressionCarcinoma cell linesBladder cancerValproic acidThroughput screening
2009
A MicroRNA expression profile defining the invasive bladder tumor phenotype
Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Neto B, LaVoie AK, Logvinenko T, Libertino JA, Summerhayes IC. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urologic Oncology Seminars And Original Investigations 2009, 29: 794-801.e1. PMID: 19945312, DOI: 10.1016/j.urolonc.2009.08.024.Peer-Reviewed Original Research